Category: Uncategorized

New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status

Milan, Italy: New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug, pembrolizumab, to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age or menopausal status. The findings, presented at the 14th European Breast Cancer Conference (EBCC 14), add to information […]

Advanced breast cancer patients denied opportunities to join clinical trials

Patient advocate calls for collaboration to improve access to trials Clinicians and the wider research community involved in treating advanced breast cancer (ABC) need to do more to help and encourage patients to join clinical trials, according to a patient advocate who is leading a study that shows only 14% of ABC patients in the […]